Jeddah, Jamjoom Pharma, one of the leading Saudi companies in the field of pharmaceutical healthcare in the Middle East and Africa region, signed a memorandum of understanding with the General Administration of Pharmaceutical Care at the Saudi Ministry of Health, with the aim of supporting the development of health and pharmaceutical personnel through training programs and educational initiatives, which contributes to improving the quality of health services and achieving the goals of the Kingdom’s Vision 2030 .

This comes as part of Jamjoom Pharma’s strategy, which aims to consolidate its role as an effective national partner in developing the health sector, through investing in developing health competencies, supporting awareness initiatives, and expanding cooperation with governmental health authorities.

Under the memorandum of understanding signed between Jamjoom Pharma and the General Directorate of Pharmaceutical Care at the Ministry of Health, the two parties will collaborate on implementing training programs and courses in administrative, technical, and specialized fields. This includes designing and developing training materials according to approved professional standards, and organizing workshops, seminars, and forums related to training and development in pharmaceutical fields. The areas of cooperation also encompass assessing the training needs of pharmacists, providing professional consultations, evaluating the impact of training programs, and exchanging expertise in professional development.

The memorandum of understanding was signed by Dr. Ahmed Samir Al-Khouli, General Manager representing Jamjoom Pharma Saudi Arabia, and Dr. Mohamed El-Shenawy, General Manager of the General Administration of Pharmaceutical Care at the Ministry of Health, in the presence of a number of officials from both sides .

Dr. Ahmed Samir Al-Khouli, General Manager of Jamjoom Pharma Saudi Arabia and representative of this collaboration , stated : “The memorandum of understanding with the General Directorate of Pharmaceutical Care at the Ministry of Health reflects Jamjoom Pharma’s commitment to supporting the development of pharmaceutical competencies and enhancing specialized professional training programs, which contributes to enabling health practitioners to keep pace with the latest developments in the health and pharmaceutical sector, and supports the objectives of developing the healthcare system in the Kingdom .”

For his part, Dr. Mohamed El Shenawy, Director General of the General Administration of Pharmaceutical Care at the Ministry of Health, said : “This agreement represents an important step in supporting the development of pharmaceutical personnel through specialized training programs and advanced educational environments that promote continuous professional development and raise performance efficiency, in partnership with one of the leading national companies in the healthcare sector .”

This agreement reflects Jamjoom Pharma’s orientation towards building sustainable strategic partnerships with governmental health authorities with the aim of developing the health sector and supporting continuing education and professional qualification programs in line with the rapid transformations taking place in the health sector in the Kingdom .

It is worth noting that Jamjoom Pharma operates in more than 37 countries across the Middle East and Africa, with core activities in Saudi Arabia, the UAE, Iraq, the Levant, Egypt, and North Africa. The company reinforces its leading position as a major provider of trusted, high-quality pharmaceuticals and consumer healthcare products across a wide range of therapeutic areas, including ophthalmology, dermatology, cardio-metabolic diseases, general medicine, and others.

-I finish-

#Company Data

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.